Skip to content

Inspection prep notes · Sterility and contamination control

Sterilization

Also called: autoclave, depyrogenation

FDA looks less at whether sterilization equipment is in place than at whether the sterilization process is validated and its effect and the state of items after sterilization are confirmed. The findings below are quoted from warning letters and FDA 483s.

What inspectors cited

1Did not validate the sterilization process or cycle

The (b)(4) sterilization process used for equipment that comes into direct contact with your products has not been adequately validated.

FDA Warning Letter · Neobiosis, LLC · 2024-06-18 · View document

In addition there is no data to support the validation/qualification of the autoclave cycle.

FDA 483 · Celltex Therapeutics Corporation · 2024-01-17 · View document

2Did not use or control biological indicators

Your firm lacked appropriate spore population verification on in-house prepared biological indicators (BIs) used in your (b)(4) sterilization (b)(4) process.

FDA Warning Letter · CareFusion 213, LLC · 2026-05-05 · View document

Operators do not use Biological Indicators (Bis) [redacted] sterilization [redacted].

FDA 483 · TAILSTORM HEALTH INC · 2026-09-29 · View document

3Did not integrity test every batch or did not report failing integrity test results

For example: On August 8, 2024, two operators performed four post-use sterilizing filter integrity tests for (b)(4) batch (b)(4) . The four tests included three failing results and the final passing result. Your operators only reported the passing result.

FDA Warning Letter · Aspen Pharmacare Holdings Limited · 2025-03-18 · View document

Sterilizing (b)(4) were not integrity tested for each batch of drug products manufactured.

FDA Warning Letter · BRS Analytical Services, LLC · 2025-10-21 · View document

4Did not sterilize and depyrogenate containers, closures or compounding equipment

Specifically, your firm does not sterilize/depyrogenate the glass beakers, [redacted] graduated cylinders, and stir bars used to make sterile drug products.

FDA 483 · Houston Rx LLC · 2026-10-01 · View document

Drug product containers and closures were not sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use.

FDA 483 · Hybrid Pharma LLC · 2026-11-13 · View document

5Did not establish a sterile hold time or could not tell whether it had been exceeded

Your cleaning validation did not establish the clean hold time (CHT) and sterile hold time (SHT) such that there is no assurance that your manufacturing equipment are free of/meet the specifications for microbiological and endotoxin levels at the time of manufacturing.

FDA 483 · Orchid Pharma Limited · 2026-04-09 · View document

The components lacked information identifying the applicable [redacted] and sterilization date needed for personnel to determine whether the established sterile hold time had been exceeded.

FDA 483 · OPS International Inc dba Olympia Pharmaceuticals · 2026-10-01 · View document

Questions to check against your procedures

  1. Is the sterilization process for equipment in direct contact with product validated?
  2. Is there data to support the validation and qualification of the autoclave cycle?
  3. Are biological indicators used in routine sterilization, and is the spore population of in-house prepared indicators verified?
  4. Are post-use sterilizing filter integrity tests done for every batch, and are failing results all recorded and reported?
  5. Are containers, closures and glassware sterilized and depyrogenated before use?
  6. Is a sterile hold time established, and can the sterilization date of each part be identified?

Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-15.

Weekly Newsletter

New GMP inspection findings, every Monday

Every Monday we email the week's new inspection records from the FDA, EMA, Health Canada and MFDS, with a short summary of the week's regulatory news. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.